Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Directional preference of the extremity: a preliminary investigation.

Maccio JR, Carlton L, Levesque K, Maccio JG, Egan L.

J Man Manip Ther. 2018 Dec;26(5):272-280. doi: 10.1080/10669817.2018.1505022. Epub 2018 Aug 13.

PMID:
30455554
2.

Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer.

O'Malley G, Treacy O, Lynch K, Naicker SD, Leonard NA, Lohan P, Dunne PD, Ritter T, Egan LJ, Ryan AE.

Cancer Immunol Res. 2018 Nov;6(11):1426-1441. doi: 10.1158/2326-6066.CIR-17-0443. Epub 2018 Sep 18. Erratum in: Cancer Immunol Res. 2019 Jan;7(1):162.

PMID:
30228206
3.

Dynamic Measures of Anxiety-Related Threat Bias: Links to Stress Reactivity.

Egan LJ, Dennis-Tiwary TA.

Motiv Emot. 2018 Aug;42(4):546-554. doi: 10.1007/s11031-018-9674-6. Epub 2018 Mar 2.

PMID:
30220752
4.

Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.

O'Connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, MacCarthy F, MacMathuna P, Mahmud N, McKiernan S, McNamara D, Mulcahy H, Murray F, O'Connor A, O'Toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D.

Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1019-1026. doi: 10.1097/MEG.0000000000001177.

PMID:
29878945
5.

Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772).

Sheridan J, Coe CA, Doran P, Egan L, Cullen G, Kevans D, Leyden J, Galligan M, O'Toole A, McCarthy J, Doherty G.

BMJ Open Gastroenterol. 2018 Jan 11;5(1):e000174. doi: 10.1136/bmjgast-2017-000174. eCollection 2018.

6.

Ten Years of the Journal of Crohn's and Colitis.

Egan LJ.

J Crohns Colitis. 2017 Sep 1;11(9):1029. doi: 10.1093/ecco-jcc/jjx113. No abstract available.

PMID:
28881877
7.

Neurocognitive assessment of emotional context sensitivity.

Myruski S, Bonanno GA, Gulyayeva O, Egan LJ, Dennis-Tiwary TA.

Cogn Affect Behav Neurosci. 2017 Oct;17(5):1058-1071. doi: 10.3758/s13415-017-0533-9.

8.

GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation.

Carlessi R, Chen Y, Rowlands J, Cruzat VF, Keane KN, Egan L, Mamotte C, Stokes R, Gunton JE, Bittencourt PIH, Newsholme P.

Sci Rep. 2017 Jun 1;7(1):2661. doi: 10.1038/s41598-017-02838-2.

9.

Inflammation-associated DNA methylation patterns in epithelium of ulcerative colitis.

Barnicle A, Seoighe C, Greally JM, Golden A, Egan LJ.

Epigenetics. 2017 Aug;12(8):591-606. doi: 10.1080/15592294.2017.1334023. Epub 2017 May 30.

10.

Hick-Hyman Law is Mediated by the Cognitive Control Network in the Brain.

Wu T, Dufford AJ, Egan LJ, Mackie MA, Chen C, Yuan C, Chen C, Li X, Liu X, Hof PR, Fan J.

Cereb Cortex. 2018 Jul 1;28(7):2267-2282. doi: 10.1093/cercor/bhx127.

PMID:
28531252
11.

Research conference summary from the 2014 International Task Force on ATP1A3-Related Disorders.

Rosewich H, Sweney MT, DeBrosse S, Ess K, Ozelius L, Andermann E, Andermann F, Andrasco G, Belgrade A, Brashear A, Ciccodicola S, Egan L, George AL Jr, Lewelt A, Magelby J, Merida M, Newcomb T, Platt V, Poncelin D, Reyna S, Sasaki M, Sotero de Menezes M, Sweadner K, Viollet L, Zupanc M, Silver K, Swoboda K.

Neurol Genet. 2017 Mar 2;3(2):e139. doi: 10.1212/NXG.0000000000000139. eCollection 2017 Apr.

12.

Completion Proctectomy for Crohn's Colitis: Lessons Learned.

Mihes Y, Hogan NM, Egan L, Joyce MR.

J Crohns Colitis. 2017 Jul 1;11(7):894-897. doi: 10.1093/ecco-jcc/jjx011.

PMID:
28158506
13.

Repeated recall and PKMζ maintain fear memories in juvenile rats.

Oliver CF, Kabitzke P, Serrano P, Egan LJ, Barr GA, Shair HN, Wiedenmayer C.

Learn Mem. 2016 Nov 15;23(12):710-713. doi: 10.1101/lm.042549.116. Print 2016 Dec.

14.

Infliximab Selectively Modulates the Circulating Blood Monocyte Repertoire in Crohn's Disease.

Slevin SM, Dennedy MC, Connaughton EP, Ribeiro A, Ceredig R, Griffin MD, Egan LJ.

Inflamm Bowel Dis. 2016 Dec;22(12):2863-2878.

PMID:
27824651
15.

Reversal of warfarin anticoagulation using prothrombin complex concentrate at 25 IU kg-1 : results of the RAPID study.

Appleby N, Groarke E, Crowley M, Wahab FA, McCann AM, Egan L, Gough D, McMahon G, O'Donghaile D, O'Keeffe D, O'Connell N.

Transfus Med. 2017 Feb;27(1):66-71. doi: 10.1111/tme.12371. Epub 2016 Oct 7.

PMID:
27714877
16.

The Capacity of Cognitive Control Estimated from a Perceptual Decision Making Task.

Wu T, Dufford AJ, Mackie MA, Egan LJ, Fan J.

Sci Rep. 2016 Sep 23;6:34025. doi: 10.1038/srep34025.

17.

Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?

O'Malley G, Heijltjes M, Houston AM, Rani S, Ritter T, Egan LJ, Ryan AE.

Oncotarget. 2016 Sep 13;7(37):60752-60774. doi: 10.18632/oncotarget.11354. Review.

18.

Neuroanatomical Alterations in High-Functioning Adults with Autism Spectrum Disorder.

Eilam-Stock T, Wu T, Spagna A, Egan LJ, Fan J.

Front Neurosci. 2016 Jun 2;10:237. doi: 10.3389/fnins.2016.00237. eCollection 2016.

19.

Differential DNA methylation patterns of homeobox genes in proximal and distal colon epithelial cells.

Barnicle A, Seoighe C, Golden A, Greally JM, Egan LJ.

Physiol Genomics. 2016 Apr;48(4):257-73. doi: 10.1152/physiolgenomics.00046.2015. Epub 2016 Jan 26.

20.

For whom the bell tolls: Neurocognitive individual differences in the acute stress-reduction effects of an attention bias modification game for anxiety.

Dennis-Tiwary TA, Egan LJ, Babkirk S, Denefrio S.

Behav Res Ther. 2016 Feb;77:105-17. doi: 10.1016/j.brat.2015.12.008. Epub 2015 Dec 18.

21.

New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease.

Slevin SM, Egan LJ.

Inflamm Bowel Dis. 2015 Dec;21(12):2909-20. doi: 10.1097/MIB.0000000000000533. Review.

PMID:
26348448
22.

European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies.

Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, Fiorino G, Gornet JM, Higgins P, Katsanos KH, Nissen L, Pellino G, Rogler G, Scaldaferri F, Szymanska E, Eliakim R; ECCO.

J Crohns Colitis. 2015 Nov;9(11):945-65. doi: 10.1093/ecco-jcc/jjv141. Epub 2015 Aug 20. No abstract available.

23.

The intestinal epithelial cell cycle: uncovering its 'cryptic' nature.

McKernan DP, Egan LJ.

Curr Opin Gastroenterol. 2015 Mar;31(2):124-9. doi: 10.1097/MOG.0000000000000154. Review.

PMID:
25603403
24.

Effect of genetic deletion or pharmacological antagonism of tumor necrosis factor alpha on colitis-associated carcinogenesis in mice.

Craven B, Zaric V, Martin A, Mureau C, Egan LJ.

Inflamm Bowel Dis. 2015 Mar;21(3):485-95. doi: 10.1097/MIB.0000000000000303.

PMID:
25581824
25.

Mesenchymal stromal cell therapy for Crohn's disease.

Liew A, O'Brien T, Egan L.

Dig Dis. 2014;32 Suppl 1:50-60. doi: 10.1159/000367826. Epub 2014 Dec 17. Review.

PMID:
25531353
26.

Targeting colon cancer cell NF-κB promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis.

Ryan AE, Colleran A, O'Gorman A, O'Flynn L, Pindjacova J, Lohan P, O'Malley G, Nosov M, Mureau C, Egan LJ.

Oncogene. 2015 Mar 19;34(12):1563-74. doi: 10.1038/onc.2014.86. Epub 2014 Apr 7.

PMID:
24704833
27.

Taking a closer look at IBD.

Egan LJ, Sandborn W.

Gut. 2014 Feb;63(2):e1. doi: 10.1136/gutjnl-2013-305424. No abstract available.

PMID:
24381262
28.
29.

Gene-set analysis is severely biased when applied to genome-wide methylation data.

Geeleher P, Hartnett L, Egan LJ, Golden A, Raja Ali RA, Seoighe C.

Bioinformatics. 2013 Aug 1;29(15):1851-7. doi: 10.1093/bioinformatics/btt311. Epub 2013 Jun 3.

PMID:
23732277
30.

Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (II).

Egan L, D'Inca R, Jess T, Pellino G, Carbonnel F, Bokemeyer B, Harbord M, Nunes P, Van der Woude J, Selvaggi F, Triantafillidis J.

J Crohns Colitis. 2014 Jan;8(1):19-30. doi: 10.1016/j.crohns.2013.04.009. Epub 2013 May 7. Review.

31.

Optimising monitoring in the management of Crohn's disease: a physician's perspective.

Papay P, Ignjatovic A, Karmiris K, Amarante H, Milheller P, Feagan B, D'Haens G, Marteau P, Reinisch W, Sturm A, Steinwurz F, Egan L, Panés J, Louis E, Colombel JF, Panaccione R.

J Crohns Colitis. 2013 Sep;7(8):653-69. doi: 10.1016/j.crohns.2013.02.005. Epub 2013 Apr 4. Review.

32.

Gastrointestinal radiation injury: prevention and treatment.

Shadad AK, Sullivan FJ, Martin JD, Egan LJ.

World J Gastroenterol. 2013 Jan 14;19(2):199-208. doi: 10.3748/wjg.v19.i2.199. Review.

33.

Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Shadad AK, Sullivan FJ, Martin JD, Egan LJ.

World J Gastroenterol. 2013 Jan 14;19(2):185-98. doi: 10.3748/wjg.v19.i2.185. Review.

34.

The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action.

Kerr DM, Harhen B, Okine BN, Egan LJ, Finn DP, Roche M.

Br J Pharmacol. 2013 Jun;169(4):808-19. doi: 10.1111/j.1476-5381.2012.02237.x.

35.

Smoking and Crohn's disease: active modification of an independent risk factor (education alone is not enough).

Kennelly RP, Subramaniam T, Egan LJ, Joyce MR.

J Crohns Colitis. 2013 Sep;7(8):631-5. doi: 10.1016/j.crohns.2012.08.019. Epub 2012 Oct 1.

PMID:
23036508
36.
37.

Inflammation, DNA methylation and colitis-associated cancer.

Hartnett L, Egan LJ.

Carcinogenesis. 2012 Apr;33(4):723-31. doi: 10.1093/carcin/bgs006. Epub 2012 Jan 10. Review.

PMID:
22235026
38.

Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor.

Kerr DM, Burke NN, Ford GK, Connor TJ, Harhen B, Egan LJ, Finn DP, Roche M.

Neuroscience. 2012 Mar 1;204:53-63. doi: 10.1016/j.neuroscience.2011.09.032. Epub 2011 Sep 19.

PMID:
21952131
39.

Mechanisms of drug toxicity or intolerance.

Egan LJ.

Dig Dis. 2011;29(2):172-6. doi: 10.1159/000323881. Epub 2011 Jul 5. Review.

PMID:
21734381
40.

Natural history of Crohn's disease: is the tide beginning to turn?

Maoláin MO, Egan LJ.

Ir Med J. 2011 Mar;104(3):69-70. No abstract available.

PMID:
21671517
41.

Clinical features, treatment, and survival of patients with colorectal cancer with or without inflammatory bowel disease.

Ali RA, Dooley C, Comber H, Newell J, Egan LJ.

Clin Gastroenterol Hepatol. 2011 Jul;9(7):584-9.e1-2. doi: 10.1016/j.cgh.2011.04.016. Epub 2011 Apr 22.

PMID:
21565283
42.

How to manage the risk of colorectal cancer in ulcerative colitis.

Ali RA, Egan LJ.

Curr Drug Targets. 2011 Sep;12(10):1424-32. Review.

PMID:
21466491
43.

Autophagosomal IkappaB alpha degradation plays a role in the long term control of tumor necrosis factor-alpha-induced nuclear factor-kappaB (NF-kappaB) activity.

Colleran A, Ryan A, O'Gorman A, Mureau C, Liptrot C, Dockery P, Fearnhead H, Egan LJ.

J Biol Chem. 2011 Jul 1;286(26):22886-93. doi: 10.1074/jbc.M110.199950. Epub 2011 Mar 31.

44.

The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival.

Rahman MK, Midtling EH, Svingen PA, Xiong Y, Bell MP, Tung J, Smyrk T, Egan LJ, Faubion WA Jr.

J Immunol. 2010 Jun 15;184(12):7247-56. doi: 10.4049/jimmunol.0901479. Epub 2010 May 7.

45.

Regulation of NF-kappaB responses by epigenetic suppression of IkappaBalpha expression in HCT116 intestinal epithelial cells.

O'Gorman A, Colleran A, Ryan A, Mann J, Egan LJ.

Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G96-G105. doi: 10.1152/ajpgi.00460.2009. Epub 2010 Apr 8.

46.

Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6.

Foran E, Garrity-Park MM, Mureau C, Newell J, Smyrk TC, Limburg PJ, Egan LJ.

Mol Cancer Res. 2010 Apr;8(4):471-81. doi: 10.1158/1541-7786.MCR-09-0496. Epub 2010 Mar 30.

47.

Diagnosis of histoplasmosis by antigen detection in BAL fluid.

Hage CA, Davis TE, Fuller D, Egan L, Witt JR 3rd, Wheat LJ, Knox KS.

Chest. 2010 Mar;137(3):623-8. doi: 10.1378/chest.09-1702. Epub 2009 Oct 16.

PMID:
19837826
48.

Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand resistance?

Plantivaux A, Szegezdi E, Samali A, Egan L.

Ann N Y Acad Sci. 2009 Aug;1171:38-49. doi: 10.1111/j.1749-6632.2009.04725.x. Review.

PMID:
19723036
49.

[Epidemiological profile of premature labor].

Egan LA, Gutiérrez AK, Cuevas MP, Lucio JR.

Ginecol Obstet Mex. 2008 Sep;76(9):542-8. Review. Spanish.

PMID:
18798461
50.

Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial.

Solem CA, Loftus EV Jr, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, Tremaine WJ, Egan LJ, Faubion WA, Schroeder KW, Pardi DS, Hanson KA, Jewell DA, Barlow JM, Fidler JL, Huprich JE, Johnson CD, Harmsen WS, Zinsmeister AR, Sandborn WJ.

Gastrointest Endosc. 2008 Aug;68(2):255-66. doi: 10.1016/j.gie.2008.02.017. Epub 2008 Jun 2.

PMID:
18513722

Supplemental Content

Support Center